Singapore, Sept. 18 -- British drugmaker GSK plc has announced plans to invest $30 billion across the United States (US) in research and development and supply chain infrastructure over the next five years.

This includes a new $1.2 billion investment in advanced manufacturing facilities and artificial intelligence (AI) and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States.

These investments build on GSK's strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States.

The $1.2 billion investment includes:

The $30 billion investment in the US includes capital invest...